The European Commission has approved Merck's (MRK) KEYTRUDA plus Paclitaxel with or without Bevacizumab for the treatment of adults with PD-L1 platinum-resistant recurrent ovarian cancer
Importance
Level 1
#GERMANY#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#MRK#US EQUITIES